3 Diagnostic Centres Chain, Water Treatment Company and Pharmaceutical Formulations Company Stocks With a Strong Future Roadmap: Vijaya Diagnostic Centre, VA Tech Wabag and Marksans Pharma
- November 11, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Vijaya Diagnostic Centre, VA Tech Wabag and Marksans Pharma: ROE of 13.8% to 18.1% and FY22 to FY26 revenue CAGR of 7.6% to 18.6%. Prices as of 10 Nov 2026.
Quick Answer
The three diagnostic chain, water and pharma stocks to watch are Vijaya Diagnostic Centre, VA Tech Wabag and Marksans Pharma. Their return on equity ranges from 13.8% to 18.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 18.6%. Vijaya Diagnostic Centre has the highest return on equity at 18.1%, while Marksans Pharma has the fastest revenue growth at 18.6% a year. Prices are based on the 10 November 2026 close, and this article is educational, not investment advice.
Diagnostic chain, water and pharma stocks bring together companies with a visible plan for the years ahead. Vijaya Diagnostic Centre, VA Tech Wabag and Marksans Pharma cover a diagnostic centres chain, a water treatment company and a pharmaceutical formulations company.
This list covers three diagnostic chain, water and pharma stocks with complete current figures: Vijaya Diagnostic Centre, VA Tech Wabag and Marksans Pharma. Every figure comes from the latest reported financials and the 10 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Diagnostic Chain, Water and Pharma Stocks?
Diagnostic chain, water and pharma stocks are listed companies that run diagnostic centres for pathology and imaging, design and build water and wastewater treatment plants, and make and sell oral and liquid medicines across many markets. Their earnings depend on test volumes, water project awards and prescription demand.
Diagnostic Chain, Water and Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Vijaya Diagnostic Centre | 1,478.3 | 14,066 | 75.0 | 59.6 | 18.1 | 0.44 |
| VA Tech Wabag | 2,009.9 | 11,717 | 29.7 | 22.7 | 14.4 | 0.09 |
| Marksans Pharma | 308.75 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
On valuation, Marksans Pharma trades at a P/E below the industry P/E, while Vijaya Diagnostic Centre and VA Tech Wabag trade above it, which reflects the growth the market already expects. Readers comparing diagnostic chain, water and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in diagnostic chain, water and pharma stocks can use the coming numbers to test whether growth is holding.
Why Do Diagnostic Chain, Water and Pharma Stocks Have a Strong Roadmap in India?
Diagnostic chain, water and pharma stocks have a strong roadmap in India because growing health awareness, heavy investment in clean water and steady global demand for affordable medicines keep widening the market for these companies.
- Diagnostics. Preventive checks are becoming routine.
- Water treatment. Cities and industry need clean water.
- Pharma. Affordable medicines reach more markets.
Why Vijaya Diagnostic Centre Features Among These Diagnostic Chain, Water and Pharma Stocks
Among the diagnostic chain, water and pharma stocks on this list, Vijaya Diagnostic Centre is a Hyderabad-headquartered diagnostics chain that offers pathology and radiology services through a network of centres, with Hyderabad and Telangana as its home base.
The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6.
Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore.
Roadmap: The plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.
What to watch: Check the revenue contribution from newer regions and the pace at which new centres turn profitable.
Why VA Tech Wabag Features Among These Diagnostic Chain, Water and Pharma Stocks
Among the pathology, water plant and medicine shares on this list, VA Tech Wabag designs, builds and operates water and wastewater treatment plants, including desalination and recycling plants, for municipal and industrial customers in India and abroad.
Revenue rose from Rs 3,012 crore in FY22 to Rs 4,038 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 132 crore in FY22 to Rs 370 crore in FY26, which works out to a compound annual growth rate of 29.4%.
In the June 2026 quarter, revenue grew 26.0% year on year to Rs 939 crore, while net profit rose 36.9% to Rs 90.1 crore. The company has a return on equity of 14.4%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 11,717 crore. The stock trades at a P/E of 29.7, above the industry P/E of 22.7.
Roadmap: Government missions for drinking water supply and sewage treatment, along with industrial water reuse, feed a long project pipeline. Operation and maintenance contracts add recurring revenue, and international orders widen the customer base.
What to watch: Monitor the order book, the share of operation and maintenance contracts and working capital cycles on large projects.
Why Marksans Pharma Features Among These Diagnostic Chain, Water and Pharma Stocks
Among the three companies on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%.
Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Vijaya Diagnostic Centre vs VA Tech Wabag vs Marksans Pharma on Key Financials
The table below sets the three diagnostic chain, water and pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Vijaya Diagnostic Centre | 475 | 835 | 15.1% | 173 | 20.7% |
| VA Tech Wabag | 3,012 | 4,038 | 7.6% | 370 | 9.2% |
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
Vijaya Diagnostic Centre posts the highest return on equity in this group at 18.1%. VA Tech Wabag has the largest FY26 revenue at Rs 4,038 crore, and Marksans Pharma shows the fastest revenue growth with a 18.6% compound annual rate. A useful habit with diagnostic chain, water and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several imaging lab, desalination and generic formulation stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Vijaya Diagnostic Centre | 195 | 240 | 22.8% |
| VA Tech Wabag | 745 | 939 | 26.0% |
| Marksans Pharma | 626 | 866 | 38.5% |
Key Risks to Check Before Investing in Diagnostic Chain, Water and Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these diagnostic chain, water and pharma stocks, the main points are: Long-term pathology, water plant and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Test volumes. Footfall and test mix can vary with seasons.
- Order timing. Project awards can shift between periods.
- Pricing pressure. Generic prices can change by market.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter diagnostic chain, water and pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Diagnostic Chain, Water and Pharma Stocks
Diagnostic chain, water and pharma stocks suit investors who prefer to study business strength before price moves. Vijaya Diagnostic Centre, VA Tech Wabag and Marksans Pharma each have a clear plan to grow. Based on the 10 November 2026 close, Vijaya Diagnostic Centre trades at Rs 1,478.3, VA Tech Wabag at Rs 2,009.9 and Marksans Pharma at Rs 308.75. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these diagnostic chain, water and pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track diagnostic chain, water and pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are diagnostic chain, water and pharma stocks?
Ans. Diagnostic chain, water and pharma stocks are listed companies that run diagnostic centres for pathology and imaging, design and build water and wastewater treatment plants, and make and sell oral and liquid medicines across many markets. Their earnings depend on test volumes, water project awards and prescription demand. This list looks at three of them, Vijaya Diagnostic Centre, VA Tech Wabag and Marksans Pharma, using reported FY22 to FY26 financials and the 10 November 2026 closing prices.
Which diagnostic chain, water and pharma stocks are covered in this list?
Ans. This list covers Vijaya Diagnostic Centre, VA Tech Wabag and Marksans Pharma. Based on the 10 November 2026 close, Vijaya Diagnostic Centre traded at Rs 1,478.3, VA Tech Wabag at Rs 2,009.9 and Marksans Pharma at Rs 308.75. Their return on equity ranges from 13.8% to 18.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 18.6%.
Why do diagnostic chain, water and pharma stocks have a strong future roadmap in India?
Ans. Diagnostic chain, water and pharma stocks have a strong roadmap in India because growing health awareness, heavy investment in clean water and steady global demand for affordable medicines keep widening the market for these companies. The main drivers are as follows. Diagnostics. Preventive checks are becoming routine. Water treatment. Cities and industry need clean water. Pharma. Affordable medicines reach more markets. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Vijaya Diagnostic Centre performed financially?
Ans. Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6. Looking ahead, the plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.
How has VA Tech Wabag performed financially?
Ans. Revenue rose from Rs 3,012 crore in FY22 to Rs 4,038 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 132 crore in FY22 to Rs 370 crore in FY26, which works out to a compound annual growth rate of 29.4%. In the June 2026 quarter, revenue grew 26.0% year on year to Rs 939 crore, while net profit rose 36.9% to Rs 90.1 crore. The company has a return on equity of 14.4%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 11,717 crore. The stock trades at a P/E of 29.7, above the industry P/E of 22.7. Looking ahead, government missions for drinking water supply and sewage treatment, along with industrial water reuse, feed a long project pipeline. Operation and maintenance contracts add recurring revenue, and international orders widen the customer base.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What risks should investors check before buying diagnostic chain, water and pharma stocks?
Ans. Investors should check a few risks before buying diagnostic chain, water and pharma stocks. Test volumes. Footfall and test mix can vary with seasons. Order timing. Project awards can shift between periods. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of diagnostic chain, water and pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 10 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
